6,418.00
0.00
(0.00%)
At close: January 30 at 11:14:58 AM CST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in CHF | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 14 | 14 |
| Avg. Estimate | 15.06B | 15.64B | 64.52B | 67.26B |
| Low Estimate | 15.06B | 15.64B | 63.03B | 64.63B |
| High Estimate | 15.06B | 15.64B | 66.56B | 68.93B |
| Year Ago Sales | 14.4B | 15.45B | 60.49B | 64.52B |
| Sales Growth (year/est) | 4.59% | 1.27% | 6.65% | 4.25% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ROGN.MX | -- | -- | -- | -- |
| S&P 500 | 9.91% | 10.33% | 14.01% | 13.75% |
Related Tickers
ZEGA.F AstraZeneca PLC
67.50
+0.75%
NVSEF Novartis AG
101.26
0.00%
BAYRY Bayer Aktiengesellschaft
5.64
-1.05%
NVS Novartis AG
104.72
-0.03%
OGN Organon & Co.
15.56
-2.57%
GSK GSK plc
35.27
-0.25%
AZN AstraZeneca PLC
70.76
-0.67%
AMGN Amgen Inc.
285.42
+0.49%
GILD Gilead Sciences, Inc.
97.20
+0.26%
ABBV AbbVie Inc.
183.90
+4.70%